Stifel Downgrades Mirati Therapeutics to Hold, Lowers Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Benjamin Burnett has downgraded Mirati Therapeutics (NASDAQ:MRTX) from Buy to Hold and lowered the price target from $83 to $59.
November 07, 2023 | 9:30 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mirati Therapeutics has been downgraded from Buy to Hold by Stifel, with a lowered price target from $83 to $59.
The downgrade from Buy to Hold by Stifel indicates a less optimistic outlook for the company. The lowered price target from $83 to $59 suggests that the analyst believes the stock is currently overvalued. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100